Washington, DC – The Association of Clinical Research Professionals (ACRP) today announces formation of a multi-stakeholder task force charged with defining the core competencies required of entry-level clinical research associates (CRAs).
The task force will identify the competencies required of entry-level CRAs (also known as monitors), develop measures of competence, and advocate for standardization of identified CRA competencies across the clinical research enterprise.
This announcement follows publication this week by ACRP of a position paper examining the current CRA workforce and calling for elimination of the commonly accepted and practiced two-year experience requirement for entry-level CRAs in favor of competence-based employment practices (see: A New Approach to Developing the CRA Workforce).
"The arbitrary 2-years' experience requirement is contributing to a shortage of CRAs in the clinical research profession and is leading to inefficiencies at contract research organization and clinical trial sponsors while doing nothing to ensure quality in clinical research," says Terri Hinkley, RN, BScN, MBA, CCRC, ACRP Interim Executive Director. "By leading this initiative ACRP plans to drive a shift in the profession that will both address the existing workforce pipeline issues and improve the quality conduct of clinical research."
As noted in ACRP's position paper, there are at least 10,000 CRA open positions in the United States alone, and there is no evidence to suggest that number will decline any time soon. A recent Brookings study, lamenting an overall employee shortage throughout the life sciences industry, singled out the CRA as one of the positions most in need of recruitment.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.